Viatris Stock Soars to 52-Week High Amid Positive Developments and Undervaluation

Viatris (VTRS) stock has surged to a new 52-week high of $15.61, reflecting robust performance over the past year. The pharmaceutical company's shares have delivered an impressive 53.96% return over the last 12 months, with a significant 64.12% increase in the past six months. InvestingPro analysis further suggests that the stock is currently undervalued, offering an attractive dividend yield of 3.08%. This upward momentum follows several positive company developments, including a raised price target from Piper Sandler and the appointment of a new Chief People and Corporate Affairs Officer. Additionally, Viatris achieved four key regulatory milestones, notably securing FDA approval for a generic injectable medication, underscoring its operational strengths.